BRCA1 and neoplasm: Several studies have shown that PARP inhibitors might be a promising therapeutic strategy for TNBC patients with BRCA1/2 mutations42,43, which can lead to the failure of double strand break repair, accumulation of genomic instability, and eventual tumor cell death44.